- O+4.59%
- world+0.1%
BlockBeats News, August 20th, according to BIT (bit.com) market data, Moderna (MRNA.O) dropped by 16%, after a more than 170% surge in the previous day's close.
Earlier reports stated that the personalized mRNA cancer vaccine jointly developed by Moderna and Merck showed significant success in a Phase 3 clinical trial for high-risk melanoma. This marks the world's first mRNA cancer therapy to demonstrate effectiveness in a large-scale Phase 3 trial. Following this announcement, Moderna's stock price skyrocketed by nearly 177% in a single day.
Disclaimer: The current content is sourced from third-party perspectives or directly translated by AI from third-party perspectives. CoinEx does not guarantee the authenticity, accuracy, and originality of the content, and it does not constitute any investment advice from CoinEx. The prices of cryptocurrencies are highly volatile, please be aware of the potential risks.
- CoinsPrice24H Change